DBV Technologies (DBVT) announced that it will present additional data from the positive VITESSE Phase 3 study of the VIASKIN Peanut Patch in children ages 4-7 years at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, in Philadelphia, taking place on February 27- March 2, 2026.
The company plans to submit a BLA to the U.S. FDA in the first half of 2026. The VIASKIN Peanut Patch has already received Breakthrough Therapy Designation, and DBV expects the filing may be eligible for priority review.
The company ended September 30, 2025, with cash of $69.8 million, providing runway into the third quarter of 2026.
The stock has traded between $3.82 to $26.18 over the past year. DBVT closed yesterday's trading at $23.80, up 7.11%, and fell in the pre-market to $22.76, down 4.37%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.